Payment overview · 2025
General Payments
$532.43
17 reported records · 8 companies
Healthcare provider profile · identity verified
Marc B Hazan, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · HUNTINGTON, NY · NPI 1952413809
Verified facts
What the public records show
CMS Open Payments records show Marc B Hazan, MD received $532.43 in general payments during 2025 across 17 reported records.
Edwards Lifesciences Corporation accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Wegovy.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $222.62 | 41.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $182.15 | 34.2% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.02 | 5.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.03 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.40 | 4.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.75 | 3.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.61 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.58 | 16 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $222.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $182.15 | 10 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.98 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 255 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 43 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
255 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 83 |
| Entresto | Sacubitril/Valsartan | 255 | 55 |
| Losartan Potassium | Losartan Potassium | 254 | 76 |
| Eliquis | Apixaban | 243 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 71 |
| Jardiance | Empagliflozin | 211 | 43 |
| Furosemide | Furosemide | 131 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 36 |
| Ezetimibe | Ezetimibe | 128 | 43 |
| Alprazolam | Alprazolam | 127 | 36 |
| Carvedilol | Carvedilol | 115 | 32 |
| Lisinopril | Lisinopril | 104 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 29 |
| Spironolactone | Spironolactone | 85 | 24 |
| Farxiga | Dapagliflozin Propanediol | 82 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 18 |
| Omeprazole | Omeprazole | 79 | 27 |
| Eplerenone | Eplerenone | 74 | 22 |
| Irbesartan | Irbesartan | 74 | 23 |
| Xarelto | Rivaroxaban | 74 | 24 |
| Allopurinol | Allopurinol | 72 | 20 |
| Ramipril | Ramipril | 68 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 23 |
| Chlorthalidone | Chlorthalidone | 58 | 18 |
| Simvastatin | Simvastatin | 58 | 19 |
| Warfarin Sodium | Warfarin Sodium | 57 | 15 |
| Gabapentin | Gabapentin | 53 | 15 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 47 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 12 |
| Valsartan | Valsartan | 43 | 12 |
| Vascepa | Icosapent Ethyl | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 15 |
| Potassium Chloride | Potassium Chloride | 40 | 16 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Metformin Hcl | Metformin Hcl | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 38 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 11 |
| Atenolol | Atenolol | 32 | 11 |
| Klor-Con M10 | Potassium Chloride | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | 12 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Wegovy | Semaglutide | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Indapamide | Indapamide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vyndamax | Tafamidis | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $532.43 · 17 records | Edwards Lifesciences Corporation | CAPVAXIVE, ENTRESTO, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, LEQVIO, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error